IFFO2

Across TCGA pan-cancer cohorts, IFFO2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IFFO2 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IFFO2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IFFO2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where IFFO2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.835	0.480	.005	31	view →
HNSC	DFS	Tertile	II,III,IV	0.988	0.887	.022	15	view →
PDAC	DFS	Tertile	All	0.941	0.364	.024	12	view →
GBM	OS	Median	All	0.808	0.942	.019	9	view →
LSCC	OS	Quartile	II,III,IV	0.943	0.669	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IFFO2–LUAD (OS)

Open the LUAD breakdown →